Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include a new Phase 3 trial in combination with CDK4/6 inhibitors in the second-line setting and a new Phase 3 trial of vepdegestrant plus Pfizer's novel CDK4 inhibitor in the first-line setting – – Prioritized second-generation PROTAC ® AR degrader ARV-766 after updated data showed robust efficacy in tumors with all AR LBD mutations in mCRPC – – Received regulatory clearance to initiate first-in-human Phase 1 clinical trials for PROTAC ® targeting BCL6 and the first neuroscience PROTAC ® degrader targeting LRRK2 – NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results f
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerGlobeNewswire
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at HC Wainwright from $90.00 to $87.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation [Seeking Alpha]Seeking Alpha
- Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised [Yahoo! Finance]Yahoo! Finance
ARVN
Earnings
- 2/27/24 - Miss
ARVN
Sec Filings
- 4/17/24 - Form ARS
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- ARVN's page on the SEC website